EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Effect of vitamin D supplementation on metabolic syndrome and atherosclerosis biomarkers in epilepsy: a randomized controlled trial

Sri Handayani, Zen Hafy, Fitri Octaviana, Zulkhair Ali, Nita Parisa, Astri Budikayanti, Dessy Agustini, Radiyati Umi Partan

Medicinski Glasnik · 2026-02-27 · 23 (1) · 111-116

DOI: 10.17392/2062-23-01 ↗
AbstractBibliografische Angaben

Abstract

<p><strong>Aim </strong>To analyze the effect of vitamin D administration on serum 25(OH)D levels and biomarkers of metabolic syndrome and atherosclerosis (homeostatic model assessment of insulin resistance [HOMA-IR], adiponectin, homocysteine, and high sensitivity C-reactive protein [hs-CRP]) in epilepsy patients receiving enzymatic antiseizure medications (ASMs).</p> <p><strong>Methods </strong>This double-blind, randomized, placebo-controlled trial randomized 40 adult epilepsy patients treated with enzymatic ASMs to receive vitamin D3 (2,000 IU/day) or placebo for 12 weeks. The primary outcome was the change in serum 25-hydroxyvitamin D (25[OH]D) levels. Secondary outcomes included changes in HOMA-IR, adiponectin, homocysteine, and hs-CRP. Data were analyzed using a per-protocol approach.</p> <p><strong>Results </strong>Thirty-four patients completed the study. Vitamin D supplementation yielded a significantly greater increase in serum 25(OH)D (10.67 &plusmn; 8.16 vs. &ndash;1.29 &plusmn; 3.96 ng/mL; p &lt; 0.001) and adiponectin (1.38 &plusmn; 3.05 vs. 0.34 &plusmn; 1.89 &micro;g/mL; p = 0.045), as well as a significantly greater reduction in hs-CRP (&ndash;6.74 &plusmn; 14.65 vs. 1.81 &plusmn; 7.75 mg/L; p = 0.041) compared with placebo. Conversely, no significant differences were observed between groups regarding the changes in HOMA-IR (&ndash;0.24 &plusmn; 3.71 vs. &ndash;0.14 &plusmn; 3.38; p = 0.940) or homocysteine (7.90 &plusmn; 1.79 vs. 8.15 &plusmn; 2.70 &micro;mol/L; p = 0.290).</p> <p><strong>Conclusion </strong>Vitamin D supplementation (2,000 IU/day) effectively restores 25(OH)D levels and improves adiponectin and hs-CRP in epilepsy patients on enzymatic ASMs, suggesting a potential benefit for cardiovascular risk reduction. However, vitamin D alone did not prevent the rise in homocysteine, likely due to the concurrent cessation of B-vitamin supplementation.</p>

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →